Concepedia

Y. Bautista

YB

5

Publications

1.4K

Citations

5

H-Index

2020

Active since

Affiliations

Centro Medico Nacional Siglo XXI(Current)

Centre Hospitalier Universitaire de Lille

Inserm

The University of Texas MD Anderson Cancer Center

Moffitt Cancer Center

Y. Bautista is an author at Centro Medico Nacional Siglo XXI specializing in cancer therapeutics, radiation oncology, and medicine.

Top concepts

Publications per year

2020–2022

5

Publications

5

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial

Paul Baas, Arnaud Scherpereel, Anna K. Nowak et al. · The Lancet · 2021 · 1.1K citations · Full text

, , +4

Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non–Small Cell Lung Cancer

Óscar Arrieta, Feliciano Barrón, Zyanya Lucía Zatarain-Barrón et al. · JAMA Oncology · 2020 · 149 citations · Full text

ID:2908 First-Line Nivolumab + Ipilimumab vs Chemotherapy in Unresectable Malignant Pleural Mesothelioma: CheckMate 743

Paul Baas, Arnaud Scherpereel, Anna K. Nowak et al. · Journal of Thoracic Oncology · 2020 · 47 citations · Full text

, , +5

First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743

Arnaud Scherpereel, Scott Antonia, Y. Bautista et al. · Lung Cancer · 2022 · 34 citations · Full text

LBA1 First-line nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) for the treatment of unresectable malignant pleural mesothelioma (MPM): Patient-reported outcomes (PROs) from CheckMate 743

Arnaud Scherpereel, Scott Antonia, Y. Bautista et al. · Annals of Oncology · 2020 · 11 citations · Full text

Rows per page

1–5 of 5